Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
Certolizumab pegol tijdens zwangerschap en borstvoeding
jan 2018 | Arthritis psoriatica, RA, Spondyloartritis